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Working with Heine was fun. From July 1969 to January1972, we worked together at the National Cancer Institute
(NCI), almost on a daily basis except for the initial 3 months that
I spent in DeVita’s lab at the beginning of my joining the NCI
Medicine Branch as a Senior Investigator. As our roles in the
newly created Lung Cancer unit got underway, our friendship
evolved: we often got together with our wives on weekends; we
were introduced to how Danish holidays were celebrated with
Lise and friends; we engaged weekly in competitive matches at
the tennis courts of Pooks Hill.
Of course, the majority of the time was spent at work,
where we indeed became soul mates. We both engaged in
clinical research, and found this an unbelievably stimulating
endeavor. Not only did we devote time to interactions with
patients, but we were handed enormous opportunities to share
in new scientific ventures that opened up in from of us at this
research hub. We worked well with our nursing team and
other personnel in a newly formed unit, with colleagues at the
VA and NCI, and with our patients. Our intellectual curiosity
was focused on using our skills to exploit new clinical
findings and to develop collaborations with all the talent
available to us. The working energy of these years were to
stay with us forever: Heine went back to Copenhagen and
rose to become the Professor at the Finsen Institute based on
his prolific contributions to define the clinical features and
treatment of small cell lung cancer. In fact, his thesis and
collected works published in 1972, upon returning to his
native Denmark, reflected the steady base of observations on
staging procedures, bone marrow involvement (that followed
our brief communication in the New England Journal of
Medicine within a few months of have begun our studies),
laparoscopic identification of liver metastases, therapeutic
concepts like prophylactic brain irradiation and multi-agent
chemotherapy, and biological features such as ectopic calci-
tonin production, among others. On my part, I also became
smitten with clinical research and emulated Heine in openly
reaching out to interact with clinicians and laboratory scien-
tists in a spirit of collaboration. For both of us, that became
the centerpiece of our careers: building a friendly academic
environment in which we could take care of patients while
participating in research and training of young oncologists.
There was always the excitement of ground breaking
research around Heine. He could be counted in coming up
with ideas during conferences, or participating in disputing
some dogma, including injecting humor. When confronted
with existing rigidity of thought, it did not stop him in
persevering and going ahead with disputed concepts and
eventually gaining an endorsement to proceed. Within 2
years, we had completed a number of clinical studies and
generated papers on the following projects: Phase I studies of
CCNU, every 2 week methotrexate, bleomycin, VM-26, and
sodium camptothecin, some supplemented by the pharmaco-
logic input of Patrick Creaven –these studies that recruited
many volunteering patients rolled out almost effortlessly. We
established many collaborations: with Saul Rosen of the NIH
Endocrinology Branch, growing the ChaGo cell line that
produced HCG; with Vince DeVita on cell kinetics of small
cell lung cancer and introducing laparoscopy for their stag-
ing; with Arman Tashjian on detecting calcitonin, and last but
not least, with Mary Matthews on the complexities of lung
cancer pathology. These achievements became the founda-
tions for the very successful Medical Oncology Branch led by
John Minna in 1975.
Heine’s personal qualities and his pioneering small cell
lung cancer studies would contribute to his many subsequent
achievements after leaving the NCI. Locally, he rose to
Professor and Chief of the Finsen Institute. As a rising star in
European organizations, Heine eventually became president
of ESMO and eventually was to serve the major roles in
oncology accreditation of burgeoning training programs. I
was fortunate to be invited to the meeting he hosted in
Copenhagen in the early 90s (to engage on a debate versus
Charles Coombes on adjuvant 5-Fluorouracil-based therapy
of colon cancer —something Heine and I had discussed on
many occasions with our VA surgical colleague George
Higgins, who headed the VA Surgical Adjuvant Group). In
1998, it was a great pleasure to speak at an all day conference
at the Finsen Institute in honor of Heine’s 60th birthday,
organized by his students and colleagues —including Fred
Hirsch, who later translocated to Denver.
Beyond those fortunate to share times with him at
International Association for the Study of Lung Cancer
(IASLC) activities, the yearly ASCO meetings were occa-
sions where many of us looked forward in getting together
with Heine and Lise. Finally, at the Chemotherapy Founda-
tion meetings during the past 2 years, we invited him share
his wisdom, and also introduce some of his trainees to our
New York audiences (a city that he and Lise loved from
Heine’s year of postgraduate hematology training at Monte-
fiore). At the dinner we shared together in November 2010,
we updated news on our families and talked about a whole
range of common interests. This congenial evening will be
remembered by us as the last image we had of Heine. We
were totally unaware that illness was later to overtake him,
and he was to embark on his final journey.
We say goodbye to our dear friend Heine with this final
thought: dedication, optimism, and friendship in the care of
patients is at the root of eventually successful clinical re-
search in oncology.
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